The Senior Leadership of the Virginia Commonwealth University (VCU) Massey Cancer Center (MCC) consists of the Director, scientific Associate Directors for Basic, Translational, Clinical, Cancer Prevention and Control Research, as well as an Associate Director for Shared Resources and an Associate Director for Research Administration and Finance. As a group, these leaders are responsible for the strategic scientific planning and tactical development of the MCC. Each of the Associate Directors provides direction for his or her area and promotes collaboration among the various areas. This Senior Leadership is complemented by the MCC strategy of Co-Leadership in each of the research programs. The translational programs have a basic science and clinical science teams of Co-Leaders, while the basic science programs are lead by Co- Leaders who have a major basic science research focus. The strength of this approach is manifested by the success of our scientific programs, as demonstrated in the overall growth of our cancer-focused research base and early phase clinical trials and translational research developed by our investigators. The Senior Leadership team is a stable, highly cohesive group of senior level cancer researchers who have successfully guided the MCC through its recent major growth in high impact collaborative scientific research and translational and clinical trial activities and established a strong positive trajectory for the future.
The Senior Leadership of MCC is instrumental in assuring that MCC fulfills its mission as an NCI-designated cancer center. The Senior Leadership develops and implements the strategic plans that facilitate the basic, translational, and clinical research and transdisciplinary interactions of the MCC members, thus serving the public health mission of detecting, treating, and eliminating cancer.
|Ginder, Gordon D (2015) Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Transl Res 165:115-25|
|Chen, Shuang; Zhang, Yu; Zhou, Liang et al. (2014) A Bim-targeting strategy overcomes adaptive bortezomib resistance in myeloma through a novel link between autophagy and apoptosis. Blood 124:2687-97|
|Youniss, Fatma M; Sundaresan, Gobalakrishnan; Graham, Laura J et al. (2014) Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling. PLoS One 9:e109162|
|Teves, Maria E; Sears, Patrick R; Li, Wei et al. (2014) Sperm-associated antigen 6 (SPAG6) deficiency and defects in ciliogenesis and cilia function: polarity, density, and beat. PLoS One 9:e107271|
|Bie, Jinghua; Wang, Jing; Yuan, Quan et al. (2014) Liver-specific transgenic expression of cholesteryl ester hydrolase reduces atherosclerosis in Ldlr-/- mice. J Lipid Res 55:729-38|
|Teramachi, Jumpei; Zhou, Hua; Subler, Mark A et al. (2014) Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget's disease of bone. J Bone Miner Res 29:1456-65|
|Nakagawa, Akito; Lui, Francine E; Wassaf, Dina et al. (2014) Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem Biol 9:2318-25|
|Sarkar, S; Azab, B; Quinn, B A et al. (2014) Chemoprevention gene therapy (CGT) of pancreatic cancer using perillyl alcohol and a novel chimeric serotype cancer terminator virus. Curr Mol Med 14:125-40|
|Dhall, Sandeep; Do, Danh; Garcia, Monika et al. (2014) A novel model of chronic wounds: importance of redox imbalance and biofilm-forming bacteria for establishment of chronicity. PLoS One 9:e109848|
|Rahmani, Mohamed; Aust, Mandy Mayo; Benson, Elisa C et al. (2014) PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo. Clin Cancer Res 20:4849-60|
Showing the most recent 10 out of 215 publications